About this trial
A national multicenter, open randomized controlled study was conducted. It is planned to invite 30 multi-center units across the country to compete for enrollment, and each multi-center will enroll 140 patients meeting colposcopic indications (70 in the conventional group and 70 in the experimental group), totaling 4200 patients. Enrolled subjects were randomly divided into two groups. Methylation test + colposcopic biopsy was performed in the conventional group, and clinical follow-up was performed according to the methylation results; in the experimental group, methylation test + colposcopic biopsy +OITS was performed, and clinical follow-up was performed according to the methylation results and OITS results. To verify the effectiveness of methylation tests and OITS in screening for CIN2+, whether they can reduce missed diagnosis of CIN2+, whether they can flag excessive colposcopic procedures, and the value of clinical follow-up for cervical lesions.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Women between the ages of 18 and 65 who have already had sex life
HPV16, 18 positive or high-risk HPV infection with cytology ≧ASC-US
No history of cervical cancer and cervical physical therapy, a complete cervix
No menstrual period, no sexual activity and vaginal medication within 48 hours
Disqualifiers
Cervical dysplasia (congenital malformation or double uterus, etc.)
History of cervical treatment (coning, ablation, or photodynamic therapy)
There are definite immunosuppression conditions, such as HIV infection or organ transplantation
Patients with severe bleeding diseases such as coagulation abnormalities or photosensitive diseases (such as porphyria, lupus erythematosus, etc.)
Trial population
There are 30 multi-center units in the country, and each center competes to enter the group. The accuracy of OITS early data was 75%, the sensitivity was 82%, and the specificity was 63%. According to 20% shedding, possible causes of shedding: error caused by severe inflammatory patients, error caused by improper operation or subjects unwilling to cooperate with follow-up. The optimal efficacy test was performed with the rate of 0.75 in the experimental group and 0.5 in the control group, and the optimal efficacy threshold was 0.1(control-experimental group), bilateral alpha was 0.05, beta was 0.2, and the sample size ratio of the two groups was 1(experimental group: Control group), each single center needs to collect 58 cases in the experimental group and 58 cases in the control group. Considering 20% shedding, the sample size of each single center is at least 70 cases in the experimental group and 70 cases in the control group, and a total of 4200 cases of all centers.
Trial design
Cohort
Prospective
Treatments tested in this trial
photoelectric detection
Diagnostic testMethylation test and colposcopic biopsy was performed in the conventional group, and clinical follow-up was performed according to the methylation results; in the experimental group, methylation test and colposcopic biopsy and OITS was performed, and clinical follow-up was performed according to the methylation results and OITS results.
Treatment groups
Trial outcomes
Primary outcomes
Sensitivity and specificity of a photoelectric image detector for cervical lesions
Sensitivity and specificity of the photoelectric detection technique relative to histopathological findings.
Secondary outcomes
Detection rate of CIN2+ by photoelectric cervical lesion image detector
The sensitivity, specificity, CIN2+ detection rate, negative predictive value and positive predictive value were compared with the results of Methylaiton, colpscopy, HPV detection and cytology.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: